Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.
作者： A P Kudelka , D Tresukosol , C L Edwards , R S Freedman , C Levenback
DOI: 10.1200/JCO.1996.14.5.1552
关键词: Cisplatin 、 Gastroenterology 、 Carcinoma 、 Toxicity 、 Surgery 、 Chemotherapy 、 Camptothecin 、 Internal medicine 、 Medicine 、 Refractory 、 Phases of clinical research 、 Topotecan
摘要: PURPOSETo determine the efficacy and toxicity of topotecan administered as a 5-day intravenous infusion in patients with advanced ovarian cancer refractory to cisplatin-based chemotherapy.PATIENTS AND METHODSThirty epithelial chemotherapy received infusions 1.5 mg/m2 delivered over 30 minutes each day for 5 days. A course was repeated every 21 The patient eligibility requirements included age > or = 18 years, Zubrod score 1,500/microL, platelet count 100,000/microL, anticipated survival 3 months.RESULTSTwenty eight were assessable response toxicity. All survival. major from administration at this dose schedule myelosuppression; required reductions. Four had neutropenic fever that hospitalizat...
sci-hub.se 参考文章(10)
G A Omura, M F Brady, H D Homesley, E Yordan, F J Major, H J Buchsbaum, R C Park, Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. Journal of Clinical Oncology. ,vol. 9, pp. 1138- 1150 ,(1991) , 10.1200/JCO.1991.9.7.1138
M Markman, T Hakes, B Reichman, J L Lewis, S Rubin, W Jones, L Almadrones, F Pizzuto, W Hoskins, Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. Journal of Clinical Oncology. ,vol. 10, pp. 243- 248 ,(1992) , 10.1200/JCO.1992.10.2.243
D S Alberts, S Green, E V Hannigan, R O'Toole, D Stock-Novack, P Anderson, E A Surwit, V K Malvlya, W A Nahhas, C J Jolles, Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. Journal of Clinical Oncology. ,vol. 10, pp. 706- 717 ,(1992) , 10.1200/JCO.1992.10.5.706
M Markman, W Hoskins, RESPONSES TO SALVAGE CHEMOTHERAPY IN OVARIAN CANCER: A CRITICAL NEED FOR PRECISE DEFINITIONS OF THE TREATED POPULATION Journal of Clinical Oncology. ,vol. 10, pp. 513- 514 ,(1992) , 10.1200/JCO.1992.10.4.513
E K Rowinsky, L B Grochow, C B Hendricks, D S Ettinger, A A Forastiere, L A Hurowitz, W P McGuire, S E Sartorius, B G Lubejko, S H Kaufmann, Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. Journal of Clinical Oncology. ,vol. 10, pp. 647- 656 ,(1992) , 10.1200/JCO.1992.10.4.647
W. J. Slichenmyer, E. K. Rowinsky, R. C. Donehower, S. H. Kaufmann, The Current Status of Camptothecin Analogues as Antitumor Agents Journal of the National Cancer Institute. ,vol. 85, pp. 271- 291 ,(1993) , 10.1093/JNCI/85.4.271
L F Liu, DNA topoisomerase poisons as antitumor drugs. Annual Review of Biochemistry. ,vol. 58, pp. 351- 375 ,(1989) , 10.1146/ANNUREV.BI.58.070189.002031
M Markman, R Rothman, T Hakes, B Reichman, W Hoskins, S Rubin, W Jones, L Almadrones, J L Lewis, Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. Journal of Clinical Oncology. ,vol. 9, pp. 389- 393 ,(1991) , 10.1200/JCO.1991.9.3.389
E. C. Kohn, G. Sarosy, A. Bicher, C. Link, M. Christian, S. M. Steinberg, M. Rothenberg, D. O. Adamo, P. Davis, F. P. Ognibene, R. E. Cunnion, E. Reed, Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. Journal of the National Cancer Institute. ,vol. 86, pp. 18- 24 ,(1994) , 10.1093/JNCI/86.1.18
L B Grochow, S H Kaufmann, R C Donehower, L Hurowitz, E K Rowinsky, B R Smith, F L McCabe, A DeLisa, R Johnson, S Ludeman, Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metabolism and Disposition. ,vol. 20, pp. 706- 713 ,(1992)